
Sign up to save your podcasts
Or


For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RFN865. CME/MOC/NCPD/AAPA credit will be available until September 23, 2025.
Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Disclosure information is available at the beginning of the video presentation.
By PVI, PeerView Institute for Medical Education4.1
2525 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RFN865. CME/MOC/NCPD/AAPA credit will be available until September 23, 2025.
Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Disclosure information is available at the beginning of the video presentation.

43,643 Listeners

137 Listeners

319 Listeners

702 Listeners

500 Listeners

28 Listeners

10 Listeners

1,382 Listeners

5 Listeners

10 Listeners

4 Listeners

2 Listeners

4 Listeners

2 Listeners

3 Listeners

5 Listeners

5 Listeners

2 Listeners

0 Listeners

9 Listeners

2 Listeners

12 Listeners

2 Listeners

4 Listeners

3 Listeners

5 Listeners

289 Listeners

263 Listeners

3,341 Listeners

1,150 Listeners

191 Listeners

88 Listeners

514 Listeners

368 Listeners

431 Listeners